Patents by Inventor Raymond F. White
Raymond F. White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5468771Abstract: A compound of structural formula ##STR1## having antihypercholesterolemic utility is produced by culturing a Streptomyces sp.Type: GrantFiled: February 2, 1994Date of Patent: November 21, 1995Assignee: Merck & Co., Inc.Inventors: Magda M. Gagliardi, Shieh-Shung T. Chen, Byron H. Arison, George M. Garrity, Leeyuan Huang, John G. MacConnell, Raymond F. White
-
Patent number: 5318901Abstract: A cyclosporin derivative with incorporated "8-(3-fluoro-D-alanine)" or "8-(2-deutero-3-fluoro-D-alanine)" has been isolated from the fermentation broth of incubating Tolypocladium inflatum MF5080 (NRRL 8044) with 3-fluoro-D-alanine or its 2-deuterated isomer respectively. The modified cyclosporins exhibit immunosuppressive properties.Type: GrantFiled: July 10, 1992Date of Patent: June 7, 1994Assignee: Merck & Co., Inc.Inventors: Arthur A. Patchett, Raymond F. White, Robert T. Goegelman
-
Patent number: 5302604Abstract: Compounds of Structural Formula (I) ##STR1## are produced by directed biosynthesis. These compounds are squalene synthetase inhibitors and thus useful as cholesterol lowering agents, antifungal agents and cancer treatment agents.Type: GrantFiled: October 6, 1992Date of Patent: April 12, 1994Assignee: Merck & Co., Inc.Inventors: Kevin M. Byrne, Shieh-Shung T. Chen, Louis Kaplan, John G. MacConnell, Brian R. Petuch, Raymond F. White, Byron H. Arison
-
Patent number: 5294627Abstract: Compounds of Structural Formula (I) ##STR1## are produced by directed biosynthesis. These compounds are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer.Type: GrantFiled: August 27, 1992Date of Patent: March 15, 1994Assignee: Merck & Co., Inc.Inventors: Bryon H. Arison, Shieh-Shung T. Chen, Raymond F. White, Brian R. Petuch
-
Patent number: 5273979Abstract: Described is a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog (Compound I) of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces, lavendulae ATCC No. 55209. Also disclosed is the C-31 methylated derivative (Compound II) of Compound I produced by enzymatic methylation using 31-O-desmethylimmunomycin O-methyl transferase, (DIMT), a methyl transferase enzyme. The macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: August 1, 1991Date of Patent: December 28, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Raymond F. White, Georgette Dezeny, Byron H. Arison, Thomas R. Beattie, Amy M. Hale, Francis Dumont
-
Patent number: 5270332Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents. The compounds also exhibit antifungal activity and are inhibitors of farnesyl-protein transferase.Type: GrantFiled: August 21, 1992Date of Patent: December 14, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Leeyuan Huang, John G. MacConnell, Jon D. Polishook, Raymond F. White
-
Patent number: 5250422Abstract: Incubation of 13.beta.-hydroxy ivermectin aglycone with a species of Bacillus subtilis or the incubation of 13-deoxy ivermectin aglycone with a mixed culture of a species of Bacillus subtilis and of Streptomyces griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.Type: GrantFiled: May 11, 1992Date of Patent: October 5, 1993Assignee: Merck & Co., Inc.Inventors: Brian R. Petuch, Edward S. Inamine, Shieh-Shung T. Chen, Raymond F. White, Byron H. Arison
-
Patent number: 5225338Abstract: The known compound, 13.beta.-13-deoxy-22,23-dihydro-avermectin -B1a/B1b Aglycone is prepared microbiologically from cultures of the novel microorganisms (MA-6762, ATCC 55069, MA-6763 ATCC 55070) or the known microorganism Streptomyces lavendulae MA-6555 (ATCC 14159 or ATCC 55330). The compound is prepared by the biotransformation of 13-deoxy-22,23-dihydro avermectin B1a/B1b aglycone which oxidizes the 13-position and epimerizes the 13-position hydroxy group.Type: GrantFiled: September 24, 1990Date of Patent: July 6, 1993Assignee: Merck & Co., Inc.Inventors: Kalinka Shumanov, Raymond F. White
-
Patent number: 5221625Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6963) ATCC No. 55230. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: January 10, 1992Date of Patent: June 22, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Raymond F. White, Georgette Dezeny, Brian R. Petuch, George M. Garrity, Byron H. Arison, Amy M. Bernick
-
Patent number: 5218125Abstract: Fermentation of the microorganism Streptomyces sp. MA6966 (ATCC 55293) in the presence of the Angiotensin II (A II) receptor antagonist ##STR1## yields a new compound hydroxylated in the 2-butyl group which is also an A II antagonist useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II antagonists.Type: GrantFiled: April 23, 1992Date of Patent: June 8, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Lydia T. So, Raymond F. White
-
Patent number: 5214153Abstract: Fermentation of the microorganism Actinoplanes sp. MA6559 (ATCC 53771) in the presence of the Angiotensin II (A II) receptor antagonist ##STR1## yields a new compound, hydroxylated in the 2-butyl group, which is also an A II antagonist useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II antagonists.Type: GrantFiled: April 23, 1992Date of Patent: May 25, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Lydia T. So, Raymond F. White
-
Patent number: 5202309Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.Type: GrantFiled: August 19, 1991Date of Patent: April 13, 1993Assignee: Merck & Co., Inc.Inventors: Robert E. Schwartz, Jerrold M. Liesch, Raymond F. White, Otto D. Hensens, Henry Joshua, Dennis M. Schmatz
-
Patent number: 5194377Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.Type: GrantFiled: August 9, 1991Date of Patent: March 16, 1993Assignee: Merck & Co., Inc.Inventors: Robert E. Schwartz, Raymond F. White
-
Patent number: 5087702Abstract: Fermentation of the microorganism Streptomyces sp. (MA6750) ATCC No. 55042 in the presence of the Angiotensin II (A II) receptor antagonist of the following structure: ##STR1## yields an analog having a shikimate sugar-like moiety attached to the tetrazole, the said analog which is also an A II antagonist useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II angatonists.Type: GrantFiled: January 30, 1991Date of Patent: February 11, 1992Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Byron H. Arison, Raymond F. White, Edward S. Inamine
-
Patent number: 5070015Abstract: Incubation of 13-deoxy ivermectin aglycone with a species of B. subtilis and of S. griseus results in the production of 13-.beta. ivermectin monoglucopyranoside as the major product and of 5-.beta. ivermectin monoglucopyranoside as the minor product.Type: GrantFiled: October 15, 1990Date of Patent: December 3, 1991Assignee: Merck & Co., Inc.Inventors: Brian R. Petuch, Shieh-Shung T. Chen, Edward S. Inamine, Raymond F. White
-
Patent number: 5049565Abstract: Fermentation of the microorganism Streptomyces sp. (MA6750) ATTC No. 55042 in the presence of the Angiotensin II (A II) receptor antagonist ##STR1## yields three analogs, each having a shikimate sugar-like moiety attached to the tetrazole, which are also A II antagonists useful in the treatment of hypertension and congestive heart failure and other indications known to respond to A II antagonists.Type: GrantFiled: December 7, 1990Date of Patent: September 17, 1991Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Raymond F. White, Byron H. Arison
-
Patent number: 4766112Abstract: There are disclosed macrolides isolated from the fermentation broth, with avermectin Bla, avermectin Blb or 22,23-dihydro avermectin Bla as a substrate, of a known microorganism identified as MA-6181. The structure of the novel compounds isolated from the microorganism are presented based upon analytical studies. The compounds are highly potent antiparasitic, insecticidal, and anthelmintic agents. Compositions for such uses are also disclosed.Type: GrantFiled: April 30, 1986Date of Patent: August 23, 1988Assignee: Merck & Co. Inc.Inventors: Robert T. Goegelman, Edward S. Inamine, Raymond F. White
-
Patent number: 4668696Abstract: There is disclosed a macrolide isolated from the fermentation broth, with 22,23-dihydro avermectin Bla aglycone as a substrate, of a known microorganism identified as MA-5853. The structure of the novel compound isolated from the microorganism is presented based upon analytical studies. The compound is a highly potent antiparasitic, insecticidal, and anthelmintic agent. Compositions for such uses are also disclosed.Type: GrantFiled: July 29, 1985Date of Patent: May 26, 1987Assignee: Merck & Co., Inc.Inventors: Robert T. Goegelman, Raymond F. White, Edward S. Inamine
-
Patent number: 4666937Abstract: There are disclosed novel compounds which are derived from 22,23-dihydro avermectin Bla aglycone, 13-deoxy-22,23 dihydro overmectin Bla aglycone and 13-deoxy-22,23-dihydro overmectin Blb aglycone. The six compounds are hydroxy adducts of the substrate avermectin compound at the 12a, 24, 24a, 26, 26a and 27 positions. The hydroxy adducts are prepared by incubating the substrate with the microorganism Cunninghamella blakesleeana and isolating the hydroxy adducts from the fermentation broth. The compounds are highly potent antiparasitic, insecticidal and anthelmintic agents.Type: GrantFiled: February 20, 1986Date of Patent: May 19, 1987Assignee: Merck & Co., Inc.Inventors: Robert T. Goegelman, Edward S. Inamine, Raymond F. White